-
Boyd, MA, Moore, CL, Molina, J-M, Wood, R, Madero, JS, Wolff, M, Ruxrungtham, K, Losso, M, Renjifo, B, Teppler, H, et al.
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
The Lancet HIV
2(2)
:
e42 -e51
2015
view publication
-
Haskelberg, H, Mallon, PWG, Hoy, J, Amin, J, Moore, C, Phanuphak, P, Ferret, S, Belloso, WH, Boyd, MA, Cooper, DA, et al.
Bone Mineral Density Over 96 Weeks in Adults Failing First-Line Therapy Randomized to Raltegravir/Lopinavir/Ritonavir Compared With Standard Second-Line Therapy.
JAIDS Journal of Acquired Immune Deficiency Syndromes
67(2)
:
161 -168
2014
view publication
-
Martin, A, Moore, C, Mallon, PWG, Hoy, J, Emery, S, Belloso, W, Phanuphak, P, Ferret, S, Cooper, DA, Boyd, MA.
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.
AIDS
27(15)
:
2403 -2411
2013
view publication
-
Boyd, MA, Kumarasamy, N, Moore, CL, Nwizu, C, Losso, MH, Mohapi, L, Martin, A, Kerr, S, Sohn, AH, Teppler, H, et al.
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.
The Lancet
381(9883)
:
2091 -2099
2013
view publication